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Abstract
Monoamine oxidase-A (MAO-A), a pro-oxidative enzyme catalyzes the  
oxidative deamination of endogenous and exogenous monoamines/neurotransmitters 
like dopamine, serotonin, norepinephrine or tyramine and converting them into their 
corresponding aldehydes and reactive oxygen species (ROS). Hyperactivity of MAO-A 
has been shown to be involved in depression, neuro-degeneration including Parkinson’s 
and Alzheimer’s diseases, neuropsychiatric disorders and cardiovascular diseases. 
Our recent results however demonstrated the involvement of MAO-A in promoting 
aggressiveness of lung carcinoma. We found both constitutive and inducible expres-
sion of MAO-A in non-small cell lung cancer cells H1299 and in A549 lung epithelial 
carcinoma cells. By using knockout (by CRISPR-Cas9 gene editing technology) or 
knockdown (using MAO-A specific esiRNA) MAO-A cells we demonstrated the role of 
MAO-A in promoting lung cancer aggressiveness and epithelial to mesenchymal tran-
sition (EMT). From our observations, we can conclude that MAO-A may be considered 
as a potential therapeutic target for the intervention and treatment of lung carcinoma.
Keywords: monoamine oxidase-A (MAO-A), non-small cell lung carcinoma, 
15-lipoxygenase, metastasis, epithelial to mesenchymal transition (EMT)
1. Introduction
Monoamine oxidase A (MAO-A) is a mitochondrial outer membrane-bound 
enzyme that catalyzes oxidative deamination of biogenic amines and subsequently 
generates reactive oxygen species (ROS) in the form of hydrogen peroxide (H2O2) as 
a catalytic by product. It is widely present in almost all mammalian cell types except 
in erythrocytes [1, 2].
It is well documented that abnormalities of MAO-A levels and activity can lead 
to neuropsychiatric disorders as it plays a vital role in the regulation of neurotrans-
mitters. Moreover, MAO-A hyperactivity has been shown to be associated with 
depression and previous reports implicate MAO-A inhibitors as effective therapeu-
tics against clinical depression and anxiety [3, 4]. Involvement of MAO-A has also 
been shown in neurodegenerative diseases including Parkinson’s and Alzheimer’s 
disease by inducing oxidative stress-mediated apoptosis [5, 6]. MAO-A deficiency 
and abnormal activity has also been associated with impulsive aggressive behavior 
[7], neuropsychiatric disorders [1], pancreatic beta cell function [8] and glucose 
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metabolism [9]. In addition to neurodegenerative disorders and neuroinflamma-
tory diseases, mounting evidences have been suggested about the contribution of 
MAO-A in cardiovascular diseases like myocardial injury [10], heart failure [11], 
cardiac cell apoptosis [12] etc.
Previously it has been shown that MAO-A has a major contribution in the 
resolution of inflammation and thus been reported as a signature marker of alter-
natively activated monocytes/macrophages [13]. Reactive oxygen species (ROS) can 
predispose cancer cells to DNA damage and cause tumor initiation and progression 
[14]. This suggests that MAO-A might have a significant role in cancer. Rybaczyk 
et al. [15] carried out a study where they have analyzed a subset of cancer datasets 
concentrating on genes involved in the serotonergic pathway. Genechip datasets 
consisting of cancerous tissue from human, mouse, rat, or zebrafish were obtained 
from the GEO database [16, 17]. Initially, obvious changes that were common in 
various types of cancers were identified by comparing gene expression between 
cancerous tissues and normal tissues for each type of cancer. This study strongly 
demonstrated that MAO-A suppression could be linked to increased risk of cancer 
and MAO-A expression was decreased in 95.4% of human cancer patients and 
94.2% of animal cancer cases compared to the non-cancerous controls [15].
In contrast, high Gleason grade or poorly differentiated prostate cancer 
exhibited increased MAO-A expression [18], and the increased level of MAO-A 
promoted prostate cancer metastasis [19, 20]. Furthermore, it was also reported 
that the overexpressed MAO-A in prostate cancer cells was the main causative agent 
for the reduced expression of E-cadherin and increased expression of vimentin 
and Twist at both mRNA and protein levels in prostate cancer [19]. These studies 
suggested a likely role of MAO-A for the progression of prostate cancer by mediat-
ing EMT. However, contradicting results were reported in case of HCC [21] and 
cholangiocarcinoma [22]. Therefore, it can be hypothesize from these reports that 
MAO-A functions across different cancer cells in a context specific manner and so, 
it is essential to further uncover the function of MAO-A in other cancers. All these 
reports indicate towards the emerging role of MAO-A in tumor growth, migration 
and metastasis. However, none of these studies revealed the role of MAO-A in lung 
cancer growth, migration and metastasis and its mechanistic regulation.
MAO-A can be present constitutively in many different types of cancer cells 
(like in H1299 lung cancer, HCT116 colorectal cancer or in LNCap prostate cancer 
cells), or it can be induced by Th2 cytokines IL-13/IL-4 in A549 lung epithelial 
carcinoma cell line or monocytic U937 cell line. In a very recent study by our group 
we showed that IL-13 mediated induction of MAO-A in human bronchial epithelial 
cell NHBE as well as in human lung carcinoma cell line A549. We also explored 
the mechanisms involved in the regulation of the expression/activity and func-
tion of MAO-A during IL-13-induction and presented evidence that Stat6, 15-LO 
and PPARγ are the critical regulators that are involved in regulating MAO-A gene 
expression and activity of A549 cells which further demonstrated the concerted 
mechanistic effects of these genes during IL-13-activation. Altogether, the IL-13/
STAT6, STAT3, STAT1/15-LO/PPARγ signaling axis for regulating MAO-A gene 
expression and function add novel insights into the resolution of inflammation and 
in the progression of lung cancer [23]. In addition to that, our recent unpublished 
observation revealed that MAO-A plays an important role in regulating cancer cell 
aggressiveness and EMT transition. Moreover, a very recent report from Huang 
et al. has provided evidence that MAO-A plays a key role in EMT and HIF-1α protein 
accumulation induced by HPV-16 E7 in NSCLC cells, suggesting that MAO-A may 
be a potential therapeutic target for HPV-related NSCLC [24]. So, based on these 
recent findings, we have focused on the potential contribution of MAO-A in lung 
cancer aggressiveness and metastasis and EMT transition. Previous literature and 
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our observations thus indicated that MAO-A could serve as a potential therapeutic 
target of lung cancer intervention and treatment.
In this chapter, we precisely highlighted the contribution of MAO-A in lung 
cancer aggressiveness and EMT and thus finally to the prognosis of the lung 
cancer patients primarily based on the observations obtained from our recent 
publication and ongoing research work and background studies. We also tried to 
explore the fact that MAO-A being a well-known contributor in neurological and 
neuropsychiatric disorders, how it could also be a tempting target of lung cancer 
treatment.
2.  MAO-A is co-induced with 15-LO in human lung cancer cells during 
IL-13 activation
15-lipoxygenase (15-LO) is a lipid peroxidating enzyme which is substantially 
induced in human peripheral blood monocytes after IL-4/IL-13 activation. This 
enzyme oxidizes polyunsaturated fatty acids like linoleic and arachidonic acids to 
their corresponding hydroperoxides like 13-S-HPODE and 15-S-HPETE [23, 24], 
which have been implicated as inflammatory mediators in cell development and in 
the pathogenesis of various diseases [25–29].
In a very recent study, our group demonstrated that MAO-A is co-induced with 
15-LO in monocytes/macrophages, normal human bronchial epithelial (NHBE) 
cells and in A549 lung epithelial carcinoma cell line in response to IL-13 treatment 
[23]. Moreover, concordant 15-LO and MAO-A induction following IL-13 stimula-
tion was also investigated in other lung epithelial cancer cells like in H1299 NSCLC. 
In H1299 cells, 15- LO expression level was very low and was not induced by IL-13. 
In contrast, MAO-A was constitutively present in H1299 cells but was not further 
induced upon IL-13 stimulation. These results thus demonstrate that in H1299 
NSCLC, MAO-A is already overexpressed and no further IL-13-dependent induction 
occurs in these cells.
3. Transcriptional regulation of MAO-A and 15-LO upon IL-13 induction
In previous reports, it was demonstrated that Stats (Stat1, Stat3 and Stat6) 
are required for controlling IL-13- mediated 15-LO and MAO-A gene expression 
[30, 31]. Along with the same line, our recent research article further confirmed 
the direct binding of Stat transcription factors (Stat1, Stat3 and Stat6) to their 
cognate DNA binding sites present in the 15- LO promoter after IL-13 stimulation 
in primary monocytes [23]. On the other hand, predicted transcription factor 
binding sites of MAO-A promoter does not show any Stat consensus sequence in 
its promoter but reveals presence of a bunch of different other transcription factor 
binding sites like Sp1, GATA, TBP and GRE [32]. To justify and validate the predic-
tion of different transcription factor binding sites located in the MAO-A promoter, 
we pursued experiment and presented evidence that in response to IL-13 stimula-
tion, Sp1 transcription factor directly binds to the cognate DNA binding sites in 
the MAO-A promoter after IL-13 stimulation in primary monocytes [23]. After 
establishing the role of Sp1 trascription factor in regulation of MAO-A activity, now 
we are trying to explore the role of other transcription factors like GATA, TBP, GRE 
in the regulation of MAO-A.
It was previously demonstrated by our group that as Egr-1 and CREB binding 
sites are present in 15-LO promoter, in case of primary human monocytes, Egr-1 
and CREB explicitly bind to their cognate sequences upon IL- 13 induction [33]. 
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In addition to that, our data also affirmed that there are two distinct diverged 
imitate signaling pathways downstream of the IL-13 receptor that regulate 15-LO 
gene expression in primary monocytes [33]. Our study revealed that other than the 
conventional IL-4Rα-Jak2-Stat3-dependent pathway [34], there exists a IL-13Rα1-
Tyk2-mediated pathway which is vital for IL-13-induced Egr-1 and CREB activation 
via MEK-ERK1/2. So, transcription factors Egr-1 and CREB plays a very crucial 
role in IL-13-induced 15-LO gene expression in primary human monocytes [33]. 
Based on these previous reports, and as 15-LO and MAO-A genes are co-induced 
upon exposure to IL-13 during alternative activation of monocytes, we further 
asked a question that whether Egr-1 and CREB transcription factors have any role 
in regulating IL-13- stimulated MAO-A gene expression in primary monocytes. Our 
experimental data strongly supported the regulatory role of transcription factors 
Egr-1 and CREB in mediating IL-13-stimulated MAO-A gene expression in primary 
monocytes probably by inducing 15-LO expression.
Therefore, collectively, the results presented previously by our group and in our 
recent study strongly suggest that Stats (Stat1, Stat3 and Stat6) as well as Egr-1 and 
CREB transcription factors are critical regulators of MAO-A activity in alternatively 
activated monocytes by IL-13.
Considering the fact that both 15-LO and MAO-A are co-induced upon IL-13 
stimulation in primary human monocytes/macrophages and in A549 cells, and 
since activity of both of them are regulated by the transcriptional activation 
of several Stats (Stat1, Stat3 and Stat6), Egr-1 and CREB in monocyte/macro-
phage and in A549 cells, we further intended to explore whether one of them is 
the upstream regulator of another. As expected, experimental results the fact 
that IL-13- induced gene expression in lung carcinoma cell line A549 15-LO 
 dependent [23].
4. IL-13-induced MAO-A contributes in lung cancer cell aggressiveness
It was previously reported that increased expression of MAO-A is associated 
with high grade aggressive prostate cancer [18, 35]. The ability of MAO-A to induce 
EMT in prostate cancer cells results in increased migratory, proliferative, invasive 
and metastatic potential through an elevation of ROS [19]. MAO-A-generated 
ROS modulates HIF1α (a master regulator of hypoxia) activity by suppressing 
PHD (oxygen dependent prolyl hydroxylases) activity. It was further verified that 
MAO-A enzymatic activity rather than the protein expression which is responsible 
for enhanced level of migration, invasion and proliferation of prostate cancer cells 
by the induction of EMT. These results thus suggest that MAO-A expression in high-
grade tumors might have a likely role in maintaining a dedifferentiated phenotype 
and promoting aggressive behavior. Based on these previous reports, our group 
also investigated the contribution of MAO-A in enhancing the aggressiveness of 
different type of cancer cells like H1299 lung cancer cells and in HCT116 colorectal 
cancer cells where MAO-A is constitutively expressed and is responsible for pro-
moting migration and invasion of these cancer cells (unpublished observations by 
our group). Based on our current observations, we also hypothesized that inducible 
MAO-A expression in A549 cells by IL-13/IL-4 might be involved in ling cancer 
progression and metastasis.
15-LO products HPODE/HPETE are well known PPARγ ligands and in our 
recent study, we have confirmed that IL-13 expression of MAO-A in lung epithelial 
carcinoma cell line A549 is dependent upon PPARγ [23]. Moreover, in our recent 
study, we have further confirmed that IL-13 stimulated A549 cell migration is 
mediated by MAO-A and requires both 15-LO and PPARγ activity. In vitro transwell 
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migration assay using the MAO-A activity inhibitor Moclobemide along with the 
15-LO inhibitor PD146176 and PPARγ antagonist GW9662 confirmed the above 
observation. In presence of Moclobemide, IL-13-induced A549 cell migration was 
reduced substantially whereas Moclobemide alone in absence of IL-13 showed no 
change compared to the unstimulated control, thereby suggesting a plausible role 
of MAO-A in A549 tumor cell migration in vitro. Similarly, significant reduction 
of migration was also observed in IL-13-activated A549 cells after treatment with 
Figure 1. 
Proposed mechanism of how IL-13 induced MAO-A cancer cell aggressiveness in lung cancer.  
IL-13-mediated activation of MAO-A expression/activity in A549 lung epithelial carcinoma cells is activated by 
IL-13/ (STAT6, STAT3, STAT1)/15-LO/PPARγ signaling axis and expression/activity of this induced MAO-A 
mediates ROS generation which is believed to have significant role on A549 cell migration, invasion and 
proliferation which are all associated with the aggressiveness of this particular cancer cell. Moreover, treatment 
of A549 cells with MAO-A specific inhibitors like moclobemide or clorgyline or esiRNA- mediated knockdown of 
MAO-A gene in A549 cells showed significant downregulation in the migration, invasion and proliferation of lung 
cancer cells. This finding marked MAO-A as a promising therapeutic target for aggressive lung cancer treatment. 
IL-13: Interleukin 13, MAO-A: Monoamine oxidase A, STAT6: Signal transducer and activator of transcription 6, 
15-LO: 15 lipoxygenase, PPARγ: Peroxisome proliferator-activated receptor gamma.
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the 15-LO activity inhibitor PD146176 and PPARγ antagonist GW9662 in a dose-
dependent manner compared to IL-13-stimulated positive control [23]. Moreover, 
we further confirmed the role of MAO-A in lung cancer cell migration and invasion 
in either MAO-A knockdown cells (using MAO-A esiRNA specific gene silenc-
ing) or MAO-A knockout cells (by using CRISPR-Cas9 gene editing technology) 
[Unpublished observations by our group].
Recently it was reported that the Th2 cytokine IL-13 contributes crucially 
in promoting EMT and enhancing aggressiveness (migration and invasion) in 
colorectal cancer (CRC) cells (HT29 and SW480 cells by triggering IL-13/IL-13Rα1/
STAT6/ZEB1 signaling axis) [36]. Recent findings from our group further suggest 
that IL-13/IL-13Rα1/Stat6 signaling axis is involved in regulating the expression/
activity of MAO-A in A549 lung epithelial carcinoma cells via a 15-lipoxygenase 
(15-LO)-dependent process involving PPARγ [23] which may be the main reason of 
promoting migratory, invasive and metastatic potential of the cancer cells (unpub-
lished observations). But these results further need to be validated in in-vivo model 
or by using high grade lung cancer patient tissue samples to conclusively comment 
on the role of MAO-A on cancer progression and metastasis. The mechanism by 
which MAO-A lung cancer cell aggressiveness is described under a schematic 
 representation in Figure 1.
5.  MAO-A plays an important role in epithelial to mesenchymal 
transition (EMT) in lung carcinoma
EMT is a vital and commutative process, during which epithelial cells transit 
from polarized, cobble stone like cells to migratory, spindle-shaped mesenchymal 
cells. Apart from the morphological changes, changes at the molecular level by losing 
expression of various epithelial markers such as E-cadherin, ZO-1 and occludin, and 
acquiring expression of mesenchymal markers including N-cadherin, vimentin, and 
fibronectin are also very common in the cells experiencing EMT [37, 38].
Various studies have suggested a robust correlation between different EMT 
markers like E-cadherin, hypoxia inducible factor 1α (HIF-1α), twist, snail and 
poor prognosis in lung cancer [39]. Specially, in case of NSCLC, expression of 
Twist, Slug, and Foxc2 was identified as important marker of recurrence-free and 
overall survival in stage I NSCLC [40]. High expression pattern of various EMT 
related markers have been identified in advanced primary lung cancer specimens, 
particularly in squamous cell carcinoma [41]. Reduced EMT markers expression 
were observed in case of brain metastasis to primary NSCLC, supporting the notion 
that disseminated tumor cells undergo EMT at the site of metastasis [42, 43]. It was 
also suggested that enhanced expression of Forkhead box M1 (FOXM1), a member 
of the Fox family of factors, may have prognostic value for patients with NSCLC, 
and FOXM1 was shown to promote metastasis by inducing EMT through activation 
of the AKT/p70S6K signaling axis [44].
Plethora of earlier reports suggested that MAO-A-mediated generation of 
excessive intracellular level of hydrogen peroxide, a major ROS species can induce 
epithelial to mesenchymal transition (EMT) in cancer cells. An extensive study by 
Wu et al. in 2014 [19] elaborately described how MAO-A affects prostate cancer 
cell (PCa) growth and metastasis and demonstrated for the first time, that MAO-A 
induces EMT and augments hypoxic responses to increase the migratory, invasive, 
and metastatic potential of PCa cells.
In a recent study, Liu et al. [45] determined the expression of MAO-A and dif-
ferent EMT markers in 45 pairs of NSCLC and matched non-tumor adjacent lung 
tissues to further explore the connection between MAO-A expression and the EMT 
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or the development of clinicopathological characteristics. From the results it was 
observed that both the protein and mRNA expression levels of MAO-A in NSCLC 
tissues were higher than those observed in the matched non-tumor adjacent lung 
tissues. Furthermore, in correlation with the previous notion, the enhanced expres-
sion of MAO-A in NSCLC tissues was positively associated with N-cadherin, Slug, 
and Twist, but negatively with E-cadherin expression. Furthermore, the elevated 
MAO-A expression in NSCLC tissues was also related with late stage NSCLC 
(Z = -2.596, P = 0.029) and lymph node metastases (Z = -2.378, P = 0.020). These 
findings indicated that MAO-A may have a role in inducing NSCLC progression by 
mediating EMT.
Next, considering the fact that high expression of monoamine oxidase A (MAO-A) 
in non-small cell lung cancer (NSCLC) is related to epithelial-mesenchymal transition 
(EMT) and the development of clinicopathological features of NSCLC, very recently, 
Yang et al. [46] tried to evaluate the role of a previously synthesized MAO-A inhibitor 
(G11) on inhibiting paclitaxel resistant NSCLC metastasis and growth. Experimental 
results showed that G11 significantly abrogated the viability of paclitaxel (PTX)-
resistant NSCLC cell lines (A549/PTX and H460/PTX). G11 also abrogated the 
expression of MAO-A in A549/PTX and H460/PTX cells, which displayed relatively 
high MAO-A expression levels. Moreover, G11 was found to impede A549/PTX and 
H460/PTX cell migration and invasion. Furthermore, the in-vivo study also suggested 
that the co-administration of G11 and paclitaxel significantly suppressed tumor 
metastasis in H460/PTX lung metastasis models.
Considering these reports, we checked the expression of different EMT related 
markers like E-cadherin, N-cadherin, twist, snail, vimentin, etc. in MAO-A esiRNA 
treated A-549 cells as well as MAO-A knockout A549 cell line (by using CRISPR-
Cas9 gene editing technology). As expected, these data confirmed regulatory role 
of MAO-A in EMT in lung carcinoma [Our unpublished observations]. Now to 
further validate the role of MAO-A in EMT and cancer metastasis, we are trying 
to explore the status of MAO-A, 15-LO and different EMT markers in lung cancer 
patient samples.
So, collectively, mounting evidences from different research reports and our 
recent observation strongly recommend further investigations for MAO-A as a 
tempting therapeutic target for lung cancer treatment.
6. Discussion
Monoamine oxidase A, an enzyme responsible for the oxidative deamination of 
biogenic amines, is well-known to be closely associated with impulsive aggressive 
behavior, anxiety, depression, and is considered as an indicator of psychological 
status [47, 48]. Recently, several studies have been focusing on the relationship 
between MAO-A expression and cancers [18–20, 49]. Initially, increased MAO-A 
expression was reported in high-grade aggressive prostate cancer, it was also dem-
onstrated that increased expression of MAO-A was capable of mediating prostate 
tumorigenesis and metastasis [18–20]. Recently, MAO-A was reported as a novel 
decision maker in apoptosis and autophagy processes occurring within hormone 
refractory neuroendocrine prostate cancer cells [29]. Moreover, clorgyline, a known 
MAO-A inhibitor, was found to display anti-oncogenic and pro-differentiation 
effects on high-grade prostate cancer cells [50]. In contrary, MAO-A inhibitor-
near-infrared dye conjugate was reported to reduce prostate tumor growth [51]. 
These findings suggest a likely role of MAO-A in mediating prostate cancer progres-
sion. However, in contrast to the previous reports of prostate cancer cells, Li et al. 
demonstrated that MAO-A expression was appreciably downregulated in clinical 
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HCC tissue samples [18], and MAO-A subdued HCC metastasis by hindering the 
adrenergic system and its transactivation of EGFR signaling [21]. Huang et al. 
also found that MAO-A expression was impeded by coordinated epigenetic and 
IL-6-driven events in human cholangiocarcinoma [22], and that overexpression of 
MAO-A suppressed cholangiocarcinoma growth and invasion [22].
So, from the above discussion it is clear that MAO-A level is regulated in dif-
ferent cancer cell lines in context specific manner. Moreover, MAO-A expression 
in high grade tumors may play a crucial role in promoting aggressive behavior of 
cancer cells. MAO-A degrades monoamine neurotransmitters by oxidative deami-
nation and produces ROS. Increased level of ROS generation can be an important 
inducer of tumorigenesis, progression and metastasis in high grade cancers. Hence 
enhanced level of MAO-A expression and aggressive behavior of cancer cells may be 
correlated in advanced grade of cancer. From the studies on different type of cancer, 
it is quite evident that MAO-A may serve as a diagnostic biomarker and can also be 
applied as a therapeutic target in the treatment of cancer.
Furthermore, in case of NSCLC, as we have discussed earlier, research article 
by Liu et al. [45] supported our findings that MAO-A expression was significantly 
increased in NSCLC tissues, which was positively associated with EMT, late stages 
and lymph node metastases of the cancer, thus supporting the notion that MAO-A 
may play a role in NSCLC progression by regulating the EMT process.
In addition to that, along with the same line, Yang et al. [46] very recently 
established the role of MAO-A in lung cancer cell metastasis and EMT transition. 
So, these findings strongly recommend MAO-A as a promising therapeutic target of 
lung cancer treatment.
In our recent report, our result has demonstrated that IL-13- induced A549 cell 
migration was significantly downregulated in presence of moclobemide, a indicat-
ing a role of moclobemide in regulating lung cancer cell aggressiveness [23]. Wang 
et al. [52] that targeting MAO-A with FDA approved antidepressants could be a 
promising treatment option for the prostate cancer. It was reported by them that 
the antiandrogen enzalutamide (Enz) has improved survival in castration resistant 
prostate cancer (CRPC) patients. However, most patients eventually develop Enz 
resistance inducing by the androgen receptor (AR) splicing variant 7 (ARv7). 
Experimental results demonstrated that elevated expression of monoamine oxi-
dase-A (MAO-A) is correlated with positive ARv7 detection in CRPC patients upon 
Enz treatment. Targeting MAO-A with phenelzine or clorgyline, the FDA-approved 
drugs for antidepression, resensitize the Enz resistant (EnzR) cells to Enz treatment 
and further subdudes EnzR cell growth in-vitro and in-vivo.
Moreover, Lee et al. [53] in 2013 have demonstrated that in case of LnCaP-LN3 
prostate cancer cells MAO-A inhibitor pargyline significantly induced cell cycle 
arrest at the G1 phase compared to the control cells. In addition, pargyline induced 
an increase in the cell death rate by promoting apoptosis. Clinical depression is a 
very common feature in prostate cancer and mounting evidences have suggested 
that MAO-A levels are frequently elevated in different cancer types and MAO-A 
inhibitors (which are basically antidepressants) can serve as repurposing drugs for 
the treatment of cancer. Zarmouh et al. have identified a novel flavonoid MAO-A 
inhibitor which shows antiproliferative effect on prostate cancer cells [54].
Our recent research and different other research articles, it is well established that 
selective inhibitors of MAO-A like moclobemide, clorgyline, pargyline or a novel 
synthetic flavonoid can efficiently reduce cancer cell aggressiveness by either inhibiting 
cancer cell migration, proliferation or promoting apoptosis. So, selective inhibitors of 
MAO-A could also be used as a promising therapeutic agents for lung cancer treatment.
Moreover, in our unpublished observation, esiRNA specific knockdown of 
MAO-A in lung cancer cell A549 have shown significant downregulation of cancer cell 
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migration, invasion and EMT transition. So, siRNA-mediated gene silencing approach 
for MAO-A could also be used as a potential therapeutic approach in lung cancer 
treatment.
7. Conclusion
In cancer cells, migration and invasion are the basic steps that control metastasis 
which is a principle cause of cancer-related death. Recent reports demonstrate that 
MAO-A is involved in promoting prostate cancer progression by inducing epithelial 
to mesenchymal transition (EMT) which ultimately causes set up of ROS, thus 
increasing the ability of migration and invasion of these cells. MAO-A enzymatic 
activity is shown to be the main causative agent for MAO-A-driven ROS generation 
in cancer cells which acts as the critical regulator of MAO-A-mediated functions like 
migration, invasion and proliferation.
Evidences from different reports and our own findings suggest that elevated 
levels of MAO-A is a key feature of advanced stage of lung carcinoma and plays 
a crucial role in lung cancer cell aggressiveness through induction of epithelial to 
mesenchimal transition. Thus it is really novel to report that an oxidative enzyme 
which is preliminarily found to be involved in depression and antisocial behavior 
now can be considered as a biomarker for lung cancer therapy.
Altogether, our results strongly support that MAO-A can be used as a potential 
therapeutic target of lung cancer treatment for the better prognosis of the disease.
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